LSI's Medtech Startup Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape.
Solenic Medical is using alternating magnetic fields to reduce implant biofilms
Infections of implants are difficult to treat. According to Solenic Medical, the gold standard for the treatment of implant biofilm formation has a failure rate of 18%, with estimated reinfection rates of approximately 9%. To resolve this, Solenic Medical is developing a non-invasive technology that heats the implant using alternating magnetic fields which can reach high temperatures that are limited to less than 1mm from the implant surface. In January 2021, the company closed a Series A round for an undisclosed amount of funding.
C. Light Technologies raises $2.5M in Seed funding round
The company is using artificial intelligence (AI) to monitor neurological health. The technology monitors eye motion at the cellular level, which is over 120x more accurate than current pupil-tracking devices currently on the market. C. Light Technologies software is first being applied to multiple sclerosis, with future plans for use in ALS, concussions, Alzheimer’s and Parkinson’s disease. According to the company, delayed diagnosis and poor monitoring of disease progression cost the US healthcare system billions of dollars a year, in addition to causing poor patient outcomes and inefficiencies.
Miracor Medical – innovative solutions for the treatment of heart disease
PiCSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) is the company’s flagship technology for the treatment of patients suffering from acute myocardial infarction (MI). The device is intended to be a first-line therapy used during percutaneous coronary intervention (PCI) to improve blood flow post MI. Impaired blood flow is a significant factor resulting in the failure of PCI. The company has raised an estimated $100M in funding.
Miracor Medical is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.
SepTec is helping healthcare providers rapidly diagnose sepsis
The company is developing a sepsis diagnostic device capable of detecting sepsis-causing pathogens in under 15 minutes. The benchtop device can be deployed bedside, where a specimen of blood can be analyzed in real time for bacterial or fungal infections. The device will allow physicians to administer the appropriate therapy, halt unnecessary administration of antibiotics, and reduce antibiotic resistance. Abbott, biomerieux, and BD are key strategics in the in vitro diagnostics market.
FEops – simulation technology for structural heart interventions
FEops has developed simulation technology that is capable of accurately predicting how devices will interact with patients using patient specific models. The solution is intended to accelerate research and development of medical devices, run simulations of clinical trials in a virtual pool of patients, and allow physicians to plan structural heart interventions. To-date, the company has raised an estimated $11.6M in funding. Some of the major competitors in the structural heart interventions market include Braile Biomedica, Edwards Lifesciences, Medtronic.
FEops is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.
Cementic – liquid nanoparticles for the prevention of infection
Cementic’s platform is based on liquid nanoparticles that deliver a sustained release of anti-infective agents to dental and mineral bone. The first application of the company’s biotechnology will be for the prevention of infection follow root canal procedures. Cementic is also developing a prototype of the technology for use in bone grafting procedure to reduce post-surgical infection. In January 2021, the company closed its first Seed round of fundraising for an undisclosed amount. Key strategics in this market include Baxter, Exactech, and Orthogen.
Learn about the hottest venture funded startups developing innovative medical technologies using Life Science Intelligence’s Medtech Startup Tracker.